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Allergic rhinitis is a predisposing factor for developing clinical asthma. Moreover, allergic
rhinitis is often associated with bronchial hyperresponsiveness (BHR). We hypothesise that
patients with asthma have more small airway involvement than those with allergic rhinitis
and BHR alone. The aim of this study was to assess peripheral and proximal NO
concentration in rhinitic subjects, and to correlate the peripheral NO concentration to the
peripheral obstruction in response to methacholine.
Patients with allergic rhinitis with or without BHR, or clinical asthma were investigated in
and out of the allergy season. Healthy subjects served as controls. Fractional exhaled NO
was performed, and peripheral NO concentration and proximal flux of NO was calculated.
Methacholine test was performed including impulse oscillometry.
Rhinitic patients with asthma demonstrate an increase in both proximal and peripheral NO
compared to those with rhinitis alone or those with BHR. There is a trend of increased
peripheral NO from patients with rhinitis only, rhinitis and BHR, to rhinitis with asthma.
The increase in peripheral NO correlated with an increased peripheral obstruction in
response to methacholine. Patients with seasonal allergic rhinitis demonstrated a decrease
in both proximal and peripheral NO in the off-season.
The results support our hypothesis that rhinitic patients with asthma have more peripheral
lung inflammation and small airway involvement compared to rhinitic patients with BHR
alone.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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E. Tufvesson et al.2322Introduction Materials and methodsAsthma and rhinitis commonly occur together and many of
those with rhinitis also have bronchial hyperresponsiveness
(BHR) to methacholine. Among the atopic asthmatics more
than 90% have allergic rhinitis, and having allergic rhinitis
has shown to be a predisposing factor for later developing
asthma.1 The transition from rhinitis only to the develop-
ment of clinical asthma is probably a gradual one, with BHR
representing an intermediate step, associated with increas-
ing lower airway inflammation and an increased risk of
future asthma development.2,3 We have previously
reported that patients with allergic rhinitis and BHR
differ from patients with clinical asthma as the asthmatics
better perceived induced bronchoconstriction. From
there, we hypothesised that the main difference between
patients with rhinitis and asthma compared with those of
rhinitis and BHR was mainly due to the differences in
geographical distribution of lower airway inflammation, i.e.
that the asthmatics had more evidence of small airway
involvement.4
Nitric oxide (NO) can be measured in exhaled air, and high
levels of NO have been shown in patients with active
asthma.5,6 Thus, high levels of NO may reflect ongoing
inflammation in the airways of the patients, and can
therefore be regarded as a non-invasive potential clinical
tool to monitor asthma.7 Smith et al.8 have recently used NO
measurements as a single successful tool to guide treatment
adjustment. In recent years it has been possible to measure
NO at different exhalation flows, and approximate the NO
concentration in the peripheral region as well as the
conducting airways.9
Involvement of peripheral airways can also be estimated
by various respiratory physiological methods. Impulse
oscillometry (IOS) is based on the principle of oscillating
pulses with different frequencies introduced to the airways
during tidal breathing. Patterns of reflecting waves can be
interpreted as airway resistance, where high frequency
waves (X20Hz) are believed to reflect resistance in central
airways, while lower frequencies (5Hz) measures total
resistance. The difference between these two parameters
(DR5–R20) subsequently reflects peripheral properties of the
respiratory tract.10
In a previous study we showed that patients with seasonal
allergic rhinitis in combination with asthma have signifi-
cantly higher levels of exhaled NO compared to
patients with rhinitis alone or patients with rhinitis and
BHR to methacholine, both during season and off-season.11
The aim of this study was to further investigate these
patient groups by using measurements of NO at different
flows to estimate the peripheral (previously described as
alveolar) NO concentration as well as proximal (previously
described as bronchial) NO flux. It has previously been shown
that there is an increase in peripheral NO concentration in
asthmatic patients,12–15 and we hypothesise that involve-
ment of the peripheral airways differs between patients
with rhinitis and concomitant asthma and patients with
rhinitis with (or without) BHR. In addition we aimed to
correlate the peripheral NO concentration to the peripheral
obstruction in response to methacholine, to strengthen
our hypothesis regarding peripheral airway involvement
in asthma.Patients
Fifty-one adult patients (30 females) with allergic rhinitis
were investigated. Twenty-six of those had concomitant
clinically diagnosed mild asthma, according to global
initiative for asthma (GINA) standards.16 The age ranged
from 18 to 58 (median 27), and they had a positive skin prick
test with sensitization to birch, timothy and/or mugwort
(ALK Abello, Copenhagen, Denmark).11 Thirty-six patients
had seasonal symptomatic allergic rhinitis and were inves-
tigated both once during pollen season (having symptoms
from nose and eyes) as well as off-season (at least 1 month
after last reported symptom). Only those with pure seasonal
allergy were investigated, i.e. those with confirmed
sensitization to perennial allergens (cat, dog, horse, house
dust mite or moulds) were excluded. Three of the asthmatic
patients inhaled corticosteroids daily (200–400 mg budeso-
nide).
A control group of 12 healthy subjects, age ranging from
19 to 56 (median 43), who did not report a history of rhinitis
or asthma, was investigated. These subjects had negative
skin prick tests and were not hyperresponsive to methacho-
line.
All subjects were non-smokers without upper respiratory
tract infection within 3 weeks prior to the investigation.
Caffeine was not allowed for 4 h, and strenuous physical
exercise two hours, prior to the investigation.
All subjects gave written informed consent, and the
ethical committee in Lund approved the study (LU412-03).
NO measurements and analysis
NO measurements were performed in accordance with
International American Thoracic Society recommenda-
tions,17 using a NIOX, nitric oxide gas analyser (Aerocrine,
AB, Stockholm, Sweden). Patients were comfortably seated,
inhaled NO depleted ambient air, and exhaled at different
flow rates (10, 50, 100 and 400ml/s) 2–4 times depending on
divergence.
Peripheral NO concentration (or alveolar concentration,
CANO) and proximal maximal NO flux (J
0
awNO
) was approxi-
mated by plotting NO-output (product of concentration and
flow) against exhalation flow (at flow 100 and 400ml/s).18
The slope and intercept of this line approximate CANO and
J0awNO , respectively.
9,19 Calculations using the flow 50ml/s
were also performed, but were not used as an increase in
slope and a decrease in the intercept was observed
confirming previous reports that linearity between NO-
output and flow is valid only for approximately 450ml/s.20
All NO measurements were done prior to bronchial
challenge test.
Airway resistance and lung reactance using
methacholine inhalation challenge test
Measurement of airway resistance and lung reactance was
performed during a methacholine challenge test as pre-
viously described.11 A MasterScope spirometer, software
version 4.5 (Erich Jaeger GmbH, Wu¨rzburg, Germany) was
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Figure 1 Peripheral NO concentration. Concentration of
peripheral NO (CANO) assessed by measuring exhaled NO at
several exhalation flow rates in patients with rhinitis (R),
rhinitis with bronchial hyperresponsiveness (R+BHR), rhinitis
and concomitant asthma (R+A) and healthy controls (Ctrl). Data
Peripheral exhaled NO in rhinitic patients 2323used for flow-volume spirometry. The test was carried out
with tidal volume triggered equipment (Aerosol Provocation
System, APS, Erich Jaeger GmbH). The APS delivered a
cumulative dose of 2000 mg methacholine in five increments,
following an initial dose of 0.9% NaCl. The challenge was
discontinued if the FEV1 declined more than 20% during the
protocol, and the PD20FEV1 was determined when FEV1 fell
below 80% of the baseline value or when the total amount of
2000 mg methacholine was delivered, 400 mg of salbutamol
were given to the subject. After 10min a new flow-volume
spirometry was carried out, to ensure that the subjects were
recuperating properly.
IOS was performed (using a Jaeger MasterScreen IOS,
Erich Jaeger GmbH), 90 s after each challenge step, prior to
the spirometry to avoid the influence of deep inspiration on
the IOS parameters. FEV1 was performed between 120 and
150 s after each challenge step. The subjects used nose clips
and pressed their hand palms against the cheeks to decrease
the upper airways shunt. For about 30 s, oscillometric
pressure impulses were superimposed to the tidal breathing
of the subject, having a pulse sequence of 5 per second and
a frequency spectrum between 5 and 35Hz. The IOS
parameters were plotted against the methacholine dose at
each challenge step and a slope value was calculated.21are expressed as individual scores and median values. Open
symbols indicate patients treated with inhaled corticosteroids.
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Data is shown as median (range). As normal distribution
could not be assumed, nonparametric tests were used.
Kruskal–Wallis test for unpaired samples was used for
comparison among the groups, and Mann–Whitney’s U-test
for unpaired samples was used for comparison between
separate groups. Wilcoxon’s test was used for paired
samples, and Spearman’s rho test for correlation analysis.
GraphPad Instat3 was used for statistical analysis, and a
p-value of less than 0.05 was considered significant.Ctrl R
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Figure 2 Proximal NO flux. Proximal maximum NO flux (J0awNO )
assessed by measuring exhaled NO at several exhalation flow
rates in patients with rhinitis (R), rhinitis with bronchial
hyperresponsiveness (R+BHR), rhinitis and concomitant asthma
(R+A) and healthy controls (Ctrl). Data are expressed as
individual scores and median values. Open symbols indicate
patients treated with inhaled corticosteroids.Results
Fractional NO
Among the 25 rhinitis patients with no concomitant asthma,
16 were bronchial hyperresponsive to methacholine.
(Though, they had no symptoms suggestive of asthma).
There was a significant difference (p ¼ 0.001) in CANO
between the groups (Fig. 1). A trend of increased CANO can
be seen from healthy controls (1.6 (0.2–2.6) ppb), patients
with rhinitis only (1.9 (0.5–3.6) ppb), rhinitis and BHR (2.4
(0.8–4.5) ppb), to rhinitis and concomitant clinical asthma
(3.3 (1.0–5.9) ppb). Moreover, patients with asthma differed
significantly from patients with rhinitis and BHR (p ¼ 0.04).
Similarly, there was a significant difference (p ¼ 0.007) in
J0awNO (Fig. 2) between the groups. Interestingly, in contrast
to CANO, no trend could be found for J
0
awNO
from healthy
controls (1.1 (0.6–2.2) nl/s), patients with rhinitis only (1.0
(0.4–2.3) nl/s) to patients with rhinitis and BHR (1.1
(0.5–3.8) nl/s), but J0awNO was increased in the asthmatic
group (2.5 (0.5–9.0) nl/s), which was distinguished from the
other groups (p ¼ 0.02 between patients with rhinitis and
BHR and patients with rhinitis and concomitant asthma).Correlation analysis
Between CANO and J
0
awNO
of NO there was a significant
correlation (p ¼ 0.02; Table 1). CANO also correlated to
several airway resistance parameters (Table 1), including
Slope–DR5–R20MCh (Fig. 3), Slope-FresMCh and Slope-AXMCh
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Table 1 Correlations between peripheral NO (CANO),
proximal NO flux ðJ0awNO Þ and airway resistance parameters
(expressed as slope/metacholine dose) in all subjects
CANO J0awNO
J0awNO 0.018 (0.30) —
R5 0.0014 (0.40) n.s.
R20 0.021 (0.29) n.s.
DR5–R20 0.0031 (0.37) n.s.
Fres 0.0008 (0.41) n.s.
AX 0.0022 (0.39) n.s.
X5 0.0012 (0.41) n.s.
Values are shown as p-values (Spearman r).
n.s. ¼ not significant.
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Figure 3 Correlation between peripheral NO and peripheral
resistance. Figure showing correlation between concentration
of peripheral NO (CANO) and Slope–DR5–R20
MCh for all patients as
well as healthy controls. Data are expressed as individual
scores. Open symbols indicate patients treated with inhaled
corticosteroids.
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Figure 4 Peripheral NO concentration in season vs. off-season.
Concentration of peripheral NO (CANO) during pollen season (s)
as well as off-season (off s) assessed by measuring exhaled NO at
several exhalation flow rates in patients with seasonal rhinitis
(R), rhinitis with bronchial hyperresponsiveness (R+BHR) and
rhinitis and concomitant asthma (R+A). Data are expressed as
paired individual scores.
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Figure 5 Proximal NO flux in season vs. off-season. Proximal
NO flux (J0awNO ) during pollen season (s) as well as off-season
(off s) assessed by measuring exhaled NO at several exhalation
flow rates in patients with seasonal rhinitis (R), rhinitis with
bronchial hyperresponsiveness (R+BHR) and rhinitis and con-
E. Tufvesson et al.2324that reflect peripheral airway reactivity, as obstruction in
response to methacholine. In contrast, proximal flux did not
correlate to any of these IOS parameters.
Only three patients with clinical asthma were treated
with inhalation steroids. None of them had decreased CANO
(Fig. 1), and all three had indication of high peripheral
obstruction in response to methacholine (Fig. 3).comitant asthma (R+A). Data are expressed as paired individual
scores.On season vs. off-season
CANO was significantly reduced from pollen season to off-
season in the group of patients with rhinitis and concomitant
clinical asthma (p ¼ 0.03). This could not be seen in the
other patient groups (patients with rhinitis with or without
BHR). Similarly, J0awNO was reduced (p ¼ 0.005) from pollen
season to off-season in the group of patients with rhinitis
and concomitant asthma, but not the other groups.
Interestingly the significant differences in CANO betweenthe groups remained off-season (p ¼ 0.007). This was not
the case for proximal flux of NO (Figs. 4 and 5).Discussion
The major finding of this study was that the peripheral NO
concentration (CANO) was increased in patients with rhinitis
ARTICLE IN PRESS
Peripheral exhaled NO in rhinitic patients 2325and concomitant asthma in comparison to patients
with rhinitis only, while patients with rhinitis and BHR
represented an intermediate step between those with
rhinitis only and those with rhinitis and asthma. CANO in
patients with rhinitis only are at the same level as controls,
which are in accordance with a previous study.22 This may
reflect absence of inflammation in the lower airways.
However, a small increase in CANO in patients with rhinitis
and BHR may reflect an initial inflammatory process in the
lower airways.
Another interesting finding was that proximal flux of NO
(J0awNO ) was significantly increased merely in patients with
rhinitis and asthma. The finding that J0awNO was increased in
patients with asthma is consistent with previous find-
ings.13,14,23 In contrast, the increase in J0awNO characterized
in patients with rhinitis and asthma was not seen in either
patients with rhinitis only, nor in patients with rhinitis and
BHR.
The increase in CANO is consistent with our hypothesis that
asthma represents a geographically more extensive inflam-
mation involving the peripheral, small airways. The correla-
tion between CANO and several of the peripheral obstruction
parameters supports the concept of asthma being an
inflammatory disease involving not only the central but also
the peripheral airways.4
There was a small but significant correlation between
J0awNO and CANO. This correlation was stronger in the
asthmatic group, indicating a more widespread and in-
creased inflammation. However, no correlation was found
between J0awNO and any of the peripheral obstruction
parameters.
We have used a linear regression model where plotting
NO-output against exhalation flow at exhalation flows
450ml/s is approximately linear in adults.20 There are
additional models,18 including a non-linear regression model
described by Silkoff et al.24 using nine different flows. Due
to our instrumentation, we are limited to 400ml/s as the
highest flow, making Silkoff’s model less suitable for our
purpose. Despite these differences we had an agreement
between the two models with the exception in patients with
high J0awNO (predominantly asthmatics). Among these pa-
tients, CANO was less than zero in several cases when using
the non-linear model, suggesting that this model may be
inadequate for these purposes.
Another newly discussed area for NO exchange is axial
diffusion and the trumpet shape of the airways.25,26 Axial
diffusion of NO transports NO from the proximal region of
the lungs to the peripheral region. When this model was
used for analysis, several patients with high J0awNO have a
negative CANO. This finding may represent noise in the
estimation of the parameters, or may suggest that the
model is not adequate for the asthmatic lung. Nonetheless,
the current model used in the analysis does not consider
axial diffusion and the trumpet shape of the airway tree,
and thus, our predicted CANO may be falsely elevated in
patients with high J0awNO .
A potential weakness of our analysis is the use of only two
flows. However, it should be noted that inclusion of the
exhaled concentration at 50ml/s decreased the intercept
and increased the slope suggesting a non-linear response
in NO-output with flow. It has been previously suggested that
a cut-off of 50ml/s for the low end of the linear region ofNO-output vs. flow is only an estimate in adults.9,19
Furthermore, in additional studies we have demonstrated
that the linear relationship holds when additional flows are
used between 100 and 400ml/s (e.g., 150, 200, 250, and
300ml/s). While the use of only two flows lessens our
statistical power, it is easier and faster for the subject to
complete and thus may offer clinical advantages.
Using the non-linear regression model it is also possible to
approximate the diffusing capacity of NO in the airways.24
The pattern was similar to J0awNO (Fig. 2), with a higher level
in the group with patients with rhinitis and concomitant
asthma in comparison to the other patient groups. Addi-
tionally, the diffusing capacity was reduced off-season (data
not shown). The diffusing capacity is proportional to the
total NO-producing surface area9,27 thus, an increase
suggests a more widespread distribution of the inflammation
in the airways.
Due to the low number of patients with inhalation steroid
treatment, it was not possible to draw any conclusions.
However, no decrease in CANO could be seen, which is in
accordance with previously published data.23,28 Interest-
ingly, it should be noted that all three patients had high
levels of both CANO as well as peripheral obstruction in
response to methacholine, despite treatment with inhala-
tion steroids.
The NO in the airways is thought to be produced mainly by
airway epithelial cells and inflammatory cells, such as
macrophages,29 and the increased amount of exhaled NO
in the airways in asthmatics may be due to increased amount
of inducible NO synthase (iNOS) as a response to increased
amount of inflammatory cytokines.30,31 Little is known about
the pattern of distribution of iNOS in the peripheral airways,
which would be of great interest.
The involvement of peripheral airways has great implica-
tions on how to interpret proximal biopsy studies, quantify-
ing the degree of inflammation in a very small part of the
central airways. Our results indicate that the geographical
distribution (i.e., the extent of inflammation) is even more
important.
We have compared different mathematical models and
can only conclude that the linear model selected give us a
little bit more consistent results. The clinical usefulness is
however not yet satisfactory, as none of the mathematical
models used today are optimal. One limitation is the
necessary discrepancy between a static trumpet shaped
model and the dynamic morphology of the lungs
with different sized airways and flow turbulence.
Moreover, the unsatisfactory NO-sensors sensitivity and the
variability of NO at high flow and low NO-concentrations, is
another critical task that need further improvements. Thus
we both need new mathematical models and better
instruments to make the estimations more reliable and
clinically useful.
In this study we have found that patients with asthma in
comparison to rhinitis only, even with BHR, have evidence of
geographically more widespread and increased inflammation
as assessed by peripheral NO concentration, which is
correlated with an increase in airway resistance. This
finding supports our hypothesis that asthma is associated
with more peripheral, small airway involvement. In addi-
tion, rhinitic patients with BHR may suggest a transitional
stage between rhinitis only and rhinitis with asthma.
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